Aaron S. Devanathan

Aaron S. Devanathan

Auto-generated profile, based on publicly available information

Aaron S. Devanathan

Center for Clinical Pharmaceutical Sciences, Department of Pharmacy and Therapeutics, School of Pharmacy University of Pittsburgh Pittsburgh Pennsylvania USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2017 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
WKWesley Kufel
Wesley Kufel
ADAaron S. Devanathan
Aaron S. Devanathan
AMAshley H. Marx
Ashley H. Marx
DWDavid J. Weber
David J. Weber
LDLindsay M. Daniels
Lindsay M. Daniels

23 March 2021 in JACCP: Journal of the American College of Clinical Pharmacy
Verified
Journal Article
Closed access
KMKathryn A. Morbitzer
Kathryn A. Morbitzer
JMJacqueline E. McLaughlin
Jacqueline E. McLaughlin
ADAaron S. Devanathan
Aaron S. Devanathan
SOSachiko Ozawa
Sachiko Ozawa
MMMary Roth McClurg
Mary Roth McClurg
CLCraig R. Lee
Craig R. Lee

20 December 2019 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
ADAaron S. Devanathan
Aaron S. Devanathan
JPJason R. Pirone
Jason R. Pirone
RARamesh Akkina
Ramesh Akkina
LRLeila Remling-Mulder
Leila Remling-Mulder
PLPaul Luciw
Paul Luciw
AKAngela D. M. Kashuba
Angela D. M. Kashuba
For HIV cure strategies like “kick and kill” to succeed, antiretroviral (ARV) drugs must reach effective concentrations in putative viral reservoirs. We characterize penetration of six ARVs in three preclinical animal models and humans. We found that standard dosing strategies in preclinical species closely mimicked tissue concentrations in humans for some, but not all, ARVs.

10 February 2019 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
ADAaron S. Devanathan
Aaron S. Devanathan
DADaijha J.C. Anderson
Daijha J.C. Anderson
MCMackenzie L. Cottrell
Mackenzie L. Cottrell
EBErin M. Burgunder
Erin M. Burgunder
ASAshley C. Saunders
Ashley C. Saunders
AKAngela D.M. Kashuba
Angela D.M. Kashuba

25 September 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
NNNoah C. Neverette
Noah C. Neverette
JDJulie B. B Dumond
Julie B. B Dumond
DMDeborah K. McMahon
Deborah K. McMahon
ADAaron S. Devanathan
Aaron S. Devanathan
The mainstay of antiretroviral therapy (ART) has been combination oral therapy. While oral ART is highly effective, nonadherence remains a chief concern. Addressing this concern in recent years is the emergence of long‐acting antiretrovirals for the treatment and prevention of HIV‐1 infection. The most recently approved long‐acting antiretroviral is the first‐in‐class capsid inhibitor lenacapavir (LEN) for heavily treatment‐experienced adults with multidrug‐resistant HIV‐1 infection. Due to its biannual subcutaneous dosing scheme to inhibit the HIV‐1 capsid, LEN exhibits unique pharmacokinetics and reinforces an evolving era of ART. In this review, we evaluate published and accepted research articles, conference proceedings, and clinical trial records to provide a comprehensive overview of LEN for treatment and preliminary data for the prevention of HIV‐1 infection. These data include clinical trials outcomes, in vitro and in vivo resistance profiles, and preclinical data supporting downstream indications. We also discuss the unique clinical pharmacology of LEN with the goal of serving as a resource toward subsequent physiologically based, population‐based, and other miscellaneous pharmacometric‐focused analyses. Given the dynamic nature of the HIV treatment and prevention research fields, we also discuss ongoing studies related to LEN for treatment‐naïve adults and for prevention. Lastly, we discuss important pharmacologic gaps in special populations, drug–drug interactions, and at the sites of action germane to HIV treatment and prevention. The information discussed in this review will provide knowledge and understanding of the unique pharmacologic properties of LEN to assist clinicians and researchers as they navigate the dynamic HIV research landscape.

31 January 2023 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
ADAaron S. Devanathan
Aaron S. Devanathan
JDJulie B. B Dumond
Julie B. B Dumond
DADaijha J.C. Anderson
Daijha J.C. Anderson
KMKristen Moody
Kristen Moody
APAmanda J. Poliseno
Amanda J. Poliseno
MCMackenzie L Cottrell
Mackenzie L Cottrell